The Venture Codex

Led · Seed · Mar 2026

Laigo Bio is developing the SureTACs platform to generate bispecific antibodies that selectively degrade disease-causing membrane proteins by pairing an E3 ligase with a target protein to trigger ubiquitination and lysosomal degradation. The approach is intended to enable highly selective elimination of disease-driving membrane targets and to produce first-in-class, dual-targeted therapies. Laigo is focusing its programs on oncology as well as autoimmune and immunology indications, including graft rejection, and is advancing multiple candidate programs. The company reports in vivo and in vitro efficacy with a claimed high degree of selectivity and improved toxicity and safety. Laigo is advancing its oncology pipeline toward clinical development and progressing three autoimmune/immunology programs with support from its recent seed financing.